Approval summary: cetuximab in combination with cisplatin or carboplatin and 5‐fluorouracil for the first‐line treatment of patients with recurrent locoregional or …
MH Cohen, H Chen, S Shord, C Fuchs, K He… - The …, 2013 - academic.oup.com
Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …
[HTML][HTML] Platinum-based chemotherapy plus cetuximab in head and neck cancer
JB Vermorken, R Mesia, F Rivera… - … England Journal of …, 2008 - Mass Medical Soc
Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …
[HTML][HTML] Translating KEYNOTE-048 into practice recommendations for head and neck cancer
P Szturz, JB Vermorken - Annals of translational medicine, 2020 - ncbi.nlm.nih.gov
In 2016, immune checkpoint inhibitors entered the therapeutic portfolio of squamous cell
carcinoma of the head and neck (SCCHN) in the second-line recurrent and/or metastatic …
carcinoma of the head and neck (SCCHN) in the second-line recurrent and/or metastatic …
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic …
JB Vermorken, J Trigo, R Hitt, P Koralewski… - Journal of clinical …, 2007 - ascopubs.org
Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …
A prospective real-world multi-center study to evaluate progression-free and overall survival of radiotherapy with cetuximab and platinum-based chemotherapy with …
M Hecht, D Hahn, P Wolber, MG Hautmann, D Reichert… - Cancers, 2021 - mdpi.com
Simple Summary Despite recent developments in immune checkpoint inhibitors, the
treatment of locoregionally recurrent head and neck squamous cell cancer (HNSCC) …
treatment of locoregionally recurrent head and neck squamous cell cancer (HNSCC) …
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
WN William Jr, ES Kim, RS Herbst - Nature Reviews Clinical Oncology, 2009 - nature.com
We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of
Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients …
Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients …
Paradigm change in first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma
E Borcoman, G Marret, C Le Tourneau - Cancers, 2021 - mdpi.com
Simple Summary Immunotherapy has made a breakthrough in the treatment of patients with
recurrent and/or metastatic head and neck squamous cell carcinoma in the second line …
recurrent and/or metastatic head and neck squamous cell carcinoma in the second line …
[HTML][HTML] Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line …
F Pontes, AR Garcia, I Domingues, MJ Sousa… - Cancer Treatment and …, 2021 - Elsevier
Background In patients with recurrent or metastatic head and neck squamous cell carcinoma
(R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect …
(R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect …
Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck
Most patients with locally advanced squamous cell carcinoma of the head and neck
(SCCHN) undergo definitive therapy, yet locoregional recurrence and metastasis are …
(SCCHN) undergo definitive therapy, yet locoregional recurrence and metastasis are …
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between …
H Sato, K Tsukahara, I Okamoto, Y Katsube… - Acta Oto …, 2019 - Taylor & Francis
Background: Combination therapy consisting of a platinum agent, 5-fluorouracil and
cetuximab (EXTREME regimen) is recommended for recurrent or metastatic squamous cell …
cetuximab (EXTREME regimen) is recommended for recurrent or metastatic squamous cell …